Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21012170 | 1.00 | BLM (0.48) | BLMLTA4HACE2GABRR1CYP1A2 | |
| SCHEMBL19303739 | 0.85 | GPR84 (0.50) | BLMTBXAS1KDM4EGPR84KDM4C | |
| SCHEMBL17381816 | 0.82 | GSR (0.48) | BLMCYP1A2 | |
| SCHEMBL20993880 | 0.82 | GSR (0.48) | BLMCYP1A2 | |
| SCHEMBL17371192 | 0.81 | L3MBTL1 (0.35) | BLMKDM4EKDM4C | |
| SCHEMBL17371168 | 0.81 | L3MBTL1 (0.35) | BLMKDM4EKDM4C | |
| SCHEMBL25587750 | 0.80 | KDM4E (0.34) | KDM4E | |
| SCHEMBL9492420 | 0.79 | KDM4E (0.36) | KDM4E | |
| SCHEMBL7754927 | 0.78 | LMNA (0.39) | BLMKDM4EKDM4C | |
| SCHEMBL7758897 | 0.78 | LMNA (0.39) | KDM4EKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376144-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO, INC. | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376144-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POLB, SNRPB2, HNRNPA2B1 | BLM 554/4885LTA4H 4262/4885ACE2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.